Skip to content

Evaluation of coronary plaque characteristics by optical coherence tomography in elderly men with coronary heart disease complicated with hypotestosterone: a prospective cohort study

Evaluation of coronary plaque characteristics by optical coherence tomography in elderly men with coronary heart disease complicated with hypotestosterone: a prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044908
Enrollment
Unknown
Registered
2021-03-31
Start date
2018-01-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Low testosterone group:Optical coherence tomography
Normal testosterone group:Optical coherence tomography

Sponsors

The Third People's Hospital of Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
65 Years to 86 Years

Inclusion criteria

Inclusion criteria: 1. Men; 2. Aged >= 65 years; 3. Coronary artery disease (stenosis >=50% in the lumen diameter of any major coronary artery) was confirmed by coronary angiography and percutaneous coronary intervention (PCI) was performed; 4. Voluntary and signed informed consent, and with good compliance.

Exclusion criteria

Exclusion criteria: 1. With gonadal, pituitary and hypothalamic diseases; 2. With prostate cancer, breast cancer or any other cancer except dark skin cancer; 3. Severe lower urinary tract syndrome (International Prostate Symptom Score, IPSS >21); 4. Prostate specific antigen (PSA) > 4ng/mL; 5. Dementia or uncontrolled depression or schizophrenia; 6. Liver enzyme increased more than 3 times the upper limit of normal; 7. Serum creatinine > 221umol/L or glomerular filtration rate 50%, collateral need use protect godet or balloon expansion), pathological changes of lesion blood vessel diameter 4.0 mm or more, OCT incomplete or lesion is not suitable for OCT imaging, SVG, Visible thrombus, complicated infection or other inflammatory diseases in the target blood vessel; 14.Severe calcification and distortion, failure to predilate successfully, and unsuitable for stent delivery and deployment; 15. Patients who are taking oral anticoagulants; 16. Suffer from autoimmune diseases; 17. HbA1c > 9.0%; 18. Uncontrolled thyroid disorders; 19. SBP > 160mmHg or DBP BBB>0mmHg; 20. BMI > 35 kg/m2; 21. Life expectancy < 12 months; 22. With poor compliance; 23. Participation in other clinical trials did not meet the primary study endpoint.

Design outcomes

Primary

MeasureTime frame
Major cardiovascular events, MACE;Plaque type;

Countries

China

Contacts

Public ContactLin Ping

The Third People's Hospital of Hangzhou

linpingyj@sina.com+86 13588762686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026